Perioperative chemo plus immunotherapy for bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bile duct cancer called intrahepatic cholangiocarcinoma that is confirmed by biopsy.
- Your tumor must be able to be surgically removed with no medical reasons against surgery.
- Your cancer must have a high risk of coming back after surgery.
- You cannot have received any previous chemotherapy or other systemic treatment for this cancer.
- You need to be in good general health, able to perform daily activities with little or no help (ECOG 0 or 1).
- Your liver function must be good, as measured by a Child-Pugh score of A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests a combination of low-dose chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (PD-1/PD-L1 antibody) for people with intrahepatic cholangiocarcinoma, a type of bile duct cancer inside the liver. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests whether adding adebrelimab to S-1 chemotherapy after surgery helps prevent bile duct cancer from coming back. It may be an option for people who have had their cancer completely removed.
Hear when a new Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.